bendamustine hydrochloride has been researched along with Lymphoma in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (13.33) | 29.6817 |
| 2010's | 30 (66.67) | 24.3611 |
| 2020's | 9 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, LC; Chen, LM; Chu, XX; Feng, XY; Li, KM; Liu, XQ; Liu, YH; Ma, JJ; Sui, JR; Wang, JY; Wei, RX; Xu, JQ | 1 |
| Feng, X; Gao, Y; Jin, M; Li, H; Li, Z; Shi, C; Song, W; Zhang, L; Zhang, M | 1 |
| Jin, M; Li, Z; Shi, C; Song, Y; Zhang, M; Zhang, P | 1 |
| Endo, T; Hamada, T; Hatta, Y; Iizuka, K; Iriyama, N; Koike, T; Kurihara, K; Miura, K; Nakagawa, M; Nakamura, H; Nakayama, T; Takahashi, H | 1 |
| Ahmad, I; Bambace, N; Bernard, L; Boisjoly, JA; Bouchard, P; Bourguignon, A; Chagnon, M; Cohen, S; Delisle, JS; Fleury, I; Kiss, T; Lachance, S; Mollica, L; Roy, DC; Roy, J; Sauvageau, G; Veilleux, O; Zehr, J | 1 |
| Assanto, GM; Capriata, M; D'Elia, GM; Del Giudice, I; Di Rocco, A; Gentile, G; Girardi, P; Malfona, F; Martelli, M; Micozzi, A; Petrucci, L; Pulsoni, A | 1 |
| Beech, A; Bishton, MJ; Fox, CP; Glover, A; Griffiths, C; Martinez-Calle, N; McMillan, A; Richardson, F; Russell, N | 1 |
| Ahmed, HE; Albeirouti, B; AlJohani, NI; Alzahrani, Z; Nasani, M; Nawaz, A; Ur Rehman, J | 1 |
| Bouredji, K; Chamorey, E; Deletie, E; Gastaud, L; Peyrade, F; Quinsat, D; Re, D; Schiappa, R; Thyss, A; Verriere, B | 1 |
| Cheson, BD; Nair, KS; Penne, M; Sarraf Yazdy, M | 1 |
| Kone, V; Kothadia, JP; Raza, A | 1 |
| Boehm, A; Keil, F; Koller, E; Menschel, E; Moestl, M; Noesslinger, T; Panny, M; Simanek, R | 1 |
| Ahn, JS; Choi, HY; Jung, SH; Kim, HJ; Kim, T; Lee, HS; Lee, JJ; Yang, DH; Yoo, HD | 1 |
| Jaksic, O; Lucijanic, M; Mitrovic, Z; Pejsa, V; Prka, Z; Vrkljan, A | 1 |
| Chantepie, S; Damaj, G; Yakoub-Agha, I | 1 |
| Guiducci, B; Isidori, A; Loscocco, F; Visani, G | 1 |
| Bacher, U; Betticher, D; Brégy, R; Egger, T; Farag, SA; Jeker, B; Mansouri Taleghani, B; Novak, U; Pabst, T; Prediletto, I; Zander, T | 1 |
| Castro, M; Cia, A; Duarte, P; Foncuberta, C; Gale, RP; Jaimovich, G; Lastiri, F; Longoni, H; Ostriz, MBR; Riera, L; Vitriu, A | 1 |
| Dreyling, M; Hallek, M; Knauf, W; Trümper, L | 1 |
| Sorensen, E | 1 |
| Cheson, BD; Derenzini, E; Zinzani, PL | 1 |
| Chamberlain, MC | 1 |
| Akutsu, M; Furukawa, Y; Hiraoka, N; Kano, Y; Kikuchi, J; Koyama, D; Mori, S; Nakamura, Y; Ueda, T; Uesawa, M; Wada, T; Yamauchi, T | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Bassett, RL; Ciurea, S; Gulbis, A; Jabbour, E; Khouri, IF; Korbling, M; Oran, B; Popat, UR; Rondon, G; Turturro, F; Wei, W | 1 |
| Ito, S; Naohiro, M; Ohigashi, H; Shimono, J; Souichi, S; Teshima, T; Yutaka, T | 1 |
| Katzka, DA; Neshatian, L | 1 |
| Gambhir, IS; Jain, A; Jangid, MK; Kumar, N; Tilak, V | 1 |
| Amorim, S; Azar, N; Béné, MC; Bijou, F; Broussais-Guillaumot, F; Cartron, G; Chantepie, SP; Choufi, B; Daguindau, E; Damaj, G; Fornecker, LM; Gac, AC; Garidi, R; Gressin, R; Guiéze, R; Gyan, E | 1 |
| Hiraki, Y; Kawano, A; Miki, K; Nomura, H; Shigematsu, H; Shimoda, S | 1 |
| Baerlocher, GM; Banz, Y; Betticher, D; Egger, T; Gilli, S; Leibundgut, K; Novak, U; Pabst, T; Rauch, D; Taleghani, BM; Zander, T | 1 |
| Rummel, MJ | 1 |
| Kalaycio, M | 1 |
| Nagi, J; Tageja, N | 1 |
| Aurer, I | 1 |
| Fiegl, M; Gastl, G; Hager, J; Oexle, H; Schnallinger, M; Schreieck, S; Stauder, R; Verdorfer, I; Waldthaler, C; Zabernigg, A; Zangerl, G | 1 |
| Leoni, LM | 2 |
| Gregory, SA; Rummel, MJ | 1 |
| Albiero, E; Bernardi, M; Castegnaro, S; Chieregato, K; Madeo, D; Rodeghiero, F; Visco, C; Zanon, C | 1 |
| Ogura, M | 1 |
| Cheson, BD | 2 |
| Schrijvers, D; Vermorken, JB | 1 |
| Boehrer, S; Chow, KU; Hoelzer, D; Knau, A; Mitrou, PS; Nowak, D; Ruthardt, M; Weidmann, E | 1 |
| Assmann, M; Bartsch, R; Eschenburg, H; Franke, A; Herold, M; Jentsch-Ullrich, K; Kahl, C; Knauf, W; Koenigsmann, M; Lakner, V; Mohren, M; Müller, G; Pasold, R | 1 |
9 review(s) available for bendamustine hydrochloride and Lymphoma
| Article | Year |
|---|---|
Bendamustine: role and evidence in lymphoma therapy, an overview.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Bendamustine in chronic lymphocytic leukemia and refractory lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Nitrogen Mustard Compounds; Randomized Controlled Trials as Topic; Rituximab; Treatment Outcome | 2008 |
Bendamustine: a new look at an old drug.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoproliferative Disorders; Nitrogen Mustard Compounds | 2009 |
Bendamustine: something old, something new.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Drug Synergism; Humans; Leukemia; Lymphoma; Lymphoproliferative Disorders; Nitrogen Mustard Compounds; Remission Induction; Rituximab | 2010 |
Changing therapeutic landscape--the last decade.
Topics: Antibodies, Monoclonal; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Drug Therapy; Humans; Immunotherapy; Lymphoma; Medical Oncology; Nitrogen Mustard Compounds; Prednisolone; Proteasome Endopeptidase Complex; Radioimmunotherapy; Treatment Outcome; Vincristine | 2011 |
Conclusion and future directions.
Topics: Animals; Antineoplastic Agents; Bendamustine Hydrochloride; DNA Damage; Humans; Lymphoma; Nitrogen Mustard Compounds | 2011 |
Bendamustine's emerging role in the management of lymphoid malignancies.
Topics: Animals; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Nitrogen Mustard Compounds | 2011 |
Phase I studies with bendamustine: an update.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Europe; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphopenia; Multiple Myeloma; Nitrogen Mustard Compounds; Research Design | 2002 |
Hematologic malignancies: new developments and future treatments.
Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides | 2002 |
3 trial(s) available for bendamustine hydrochloride and Lymphoma
| Article | Year |
|---|---|
BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Combinations; Female; Graft vs Host Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Rituximab; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).
Topics: Adult; Aged; Bendamustine Hydrochloride; Female; Germany; Hematology; Humans; Lymphoma; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Societies, Medical; Time Factors; Vidarabine | 2004 |
33 other study(ies) available for bendamustine hydrochloride and Lymphoma
| Article | Year |
|---|---|
[Safety and the short-term efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Transplantation Conditioning; Transplantation, Autologous | 2022 |
The potential efficacy and mechanism of bendamustine in entra-nodal NK/T cell lymphoma.
Topics: Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Bendamustine Hydrochloride; Caspases; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Etoposide; Humans; Lymphoma; Lymphoma, T-Cell; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Ribose; Tumor Suppressor Protein p53 | 2022 |
Brentuxinmab vedotin, alone or combine with bendamustine in the treatment of natural killer T cell lymphoma.
Topics: Bendamustine Hydrochloride; Humans; Lymphoma; Lymphoma, T-Cell; Natural Killer T-Cells | 2022 |
Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience.
Topics: Aged; Antiviral Agents; Bendamustine Hydrochloride; Cytomegalovirus; Cytomegalovirus Infections; Humans; Lymphoma; Retrospective Studies; Risk Factors | 2023 |
Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Retrospective Studies; Transplantation, Autologous | 2023 |
Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study.
Topics: Antibodies, Monoclonal; Bendamustine Hydrochloride; COVID-19; Humans; Lymphoma; Retrospective Studies; SARS-CoV-2 | 2023 |
A comparison of bendamustine-EAM versus BEAM conditioning for autogolous stem cell transplant in lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Stem Cell Transplantation; Transplantation Conditioning | 2020 |
Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study.
Topics: Bendamustine Hydrochloride; Cardiotoxicity; Carmustine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Mucositis; Retrospective Studies; Transplantation, Autologous | 2021 |
Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; Female; Humans; Lymphoma; Male; Middle Aged; Neutropenia; Rituximab | 2018 |
Extended Follow-up of Patients Treated With Bendamustine for Lymphoid Malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Infections; Leukemia, Lymphoid; Lymphoma; Male; Middle Aged; Retreatment; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Successful Treatment of a Patient With Gastric Mucosa-Associated Lymphoma.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Endoscopy, Digestive System; Female; Gastric Mucosa; Histocytochemistry; Humans; Immunohistochemistry; Lymphoma; Middle Aged; Rituximab; Stomach Neoplasms; Treatment Outcome | 2018 |
High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2018 |
Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Central Nervous System Neoplasms; Female; Humans; Lymphoma; Male; Middle Aged; Pilot Projects; Salvage Therapy | 2018 |
Bendamustine-based conditioning prior to autologous stem cell transplantation is associated with high rate of febrile neutropenia and higher mortality.
Topics: Bendamustine Hydrochloride; Febrile Neutropenia; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Transplantation Conditioning; Transplantation, Autologous | 2019 |
Be ever cautious until the truth is proven.
Topics: Bendamustine Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Transplantation, Autologous | 2019 |
Benda-EAM prior to ASCT and renal toxicity: Much ado about nothing.
Topics: Bendamustine Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Kidney; Lymphoma; Transplantation, Autologous | 2019 |
High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Humans; Incidence; Kidney; Lymphoma; Male; Multiple Myeloma | 2019 |
CBeV (cyclophosphamide, bendamustine and etoposide) pre-autotransplant conditioning in persons with lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Transplantation Conditioning; Transplantation, Autologous | 2020 |
[Current and future indications for bendamustine: chronic lymphocytic leukemia, indolent lymphoma, mantle cell lymphoma and diffuse large B-cell lymphomas].
Topics: Animals; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Dose-Response Relationship, Drug; Forecasting; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Nitrogen Mustard Compounds | 2013 |
Managing patients with indolent lymphoma treated with bendamustine: a nursing perspective.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Humans; Lymphoma; Nitrogen Mustard Compounds | 2013 |
Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Central Nervous System Neoplasms; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2014 |
Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Cytarabine; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Inhibitory Concentration 50; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrimidines; Rituximab | 2014 |
Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Humans; Lymphocyte Count; Lymphoma; Lymphopenia; Maintenance Chemotherapy; Rituximab | 2015 |
A Hidden Cause of Dysphagia. Primary Esophageal Lymphoma.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Deglutition Disorders; Endosonography; Esophageal Neoplasms; Humans; Lymphoma; Male; Neoplasm Grading; Nitrogen Mustard Compounds; Rituximab; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Lymphoma without Lymphadenopathy.
Topics: Aged; Bendamustine Hydrochloride; Humans; Lymphadenopathy; Lymphoma; Male; Rituximab | 2015 |
Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 cases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Combined Modality Therapy; Female; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cells; Retreatment; Retrospective Studies | 2016 |
Two cases of malignant lymphoma with reactivation of resolved hepatitis B virus infection after bendamustine hydrochloride monotherapy.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Hepatitis B; Hepatitis B virus; Humans; Lymphoma; Male; Middle Aged; Recurrence; Virus Activation | 2016 |
BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Carmustine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Austria; Bendamustine Hydrochloride; Child; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Feasibility Studies; Female; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoproliferative Disorders; Male; Middle Aged; Nitrogen Mustard Compounds; Opportunistic Infections; Pancytopenia; Retrospective Studies; Rituximab; Treatment Outcome | 2011 |
The evolving role of bendamustine in lymphoid malignancy: understanding the drug and its mechanism of action--introduction.
Topics: Animals; Antineoplastic Agents; B-Lymphocytes; Bendamustine Hydrochloride; Humans; Lymphoma; Nitrogen Mustard Compounds | 2011 |
Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bendamustine Hydrochloride; Cell Cycle; Cell Line, Tumor; Cytarabine; Humans; Leukemia; Leukemia, B-Cell; Leukemia, T-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Nitrogen Mustard Compounds | 2012 |
Letter from the editor.
Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Congresses as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Nitrogen Mustard Compounds | 2012 |
Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bendamustine Hydrochloride; Carrier Proteins; Caspases; Cladribine; Co-Repressor Proteins; Cytochrome c Group; Cytoskeletal Proteins; Down-Regulation; Doxorubicin; Drug Synergism; Enzyme Activation; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Lymphoma; Mitochondrial Proteins; Mitoxantrone; Molecular Chaperones; Nitrogen Mustard Compounds; Nuclear Proteins; Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2003 |